June 23 (Reuters) - Compass Pathways ( CMPS ) said on
Monday its experimental psilocybin-based therapy helped
significantly reduce symptoms of difficult-to-treat depression
in a late-stage study.
(Reporting by Mariam Sunny and Christy Santhosh in Bengaluru;
Editing by Mrigank Dhaniwala)